Cargando…

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Previous clinical trials indicate that 10%–25% of patients received genomically matched therapy after comprehensive genomic profiling (CGP) tests. However, the clinical utility of CGP tests has not been assessed in clinical practice. We assessed the clinical utility of CGP tests for advanced or meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ida, Hanae, Koyama, Takafumi, Mizuno, Takaaki, Sunami, Kuniko, Kubo, Takashi, Sudo, Kazuki, Tao, Kayoko, Hirata, Makoto, Yonemori, Kan, Kato, Ken, Okusaka, Takuji, Ohe, Yuichiro, Matsui, Yoshiyuki, Yamazaki, Naoya, Ogawa, Chitose, Kawai, Akira, Narita, Yoshitaka, Esaki, Minoru, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746060/ https://www.ncbi.nlm.nih.gov/pubmed/36106376 http://dx.doi.org/10.1111/cas.15586

Ejemplares similares

PEDT-12 NATIONWIDE LANDSCAPE OF GENOMIC ANALYSIS OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS
por: Watanabe, Yuko, et al.
Publicado: (2022)

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world
por: Kaku, Sawako, et al.
Publicado: (2022)

Correction to: Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world
por: Kaku, Sawako, et al.
Publicado: (2022)

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
por: Hamamoto, Ryuji, et al.
Publicado: (2022)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
por: Omura, Takaki, et al.
Publicado: (2022)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
por: Mizuno, Takaaki, et al.
Publicado: (2022)

Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023)

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
por: Sunami, Kuniko, et al.
Publicado: (2019)

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer
por: Yagishita, Shigehiro, et al.
Publicado: (2015)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
por: So, Clara, et al.
Publicado: (2022)

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial
por: Okuma, Hitomi S., et al.
Publicado: (2020)

Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022)

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease
por: Udagawa, Chihiro, et al.
Publicado: (2019)

Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report
por: Ito, Munehiro, et al.
Publicado: (2020)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix
por: Mizuno, Takaaki, et al.
Publicado: (2020)

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
por: Mizuno, Sho, et al.
Publicado: (2023)

Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure
por: Mizuno, Takaaki, et al.
Publicado: (2020)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

Lung adenocarcinoma in a patient with a cis EGFR L858R‐K860I doublet mutation identified using NGS‐based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib
por: Onozawa, Hiroto, et al.
Publicado: (2020)

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
por: Okusaka, Takuji, et al.
Publicado: (2023)

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2020)

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2021)

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2023)

Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
por: Morofuji, Noriaki, et al.
Publicado: (2016)

A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
por: Sunami, Kuniko, et al.
Publicado: (2023)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing
por: Kato, Mamoru, et al.
Publicado: (2018)

Targeted Therapy for Biliary Tract Cancer
por: Furuse, Junji, et al.
Publicado: (2011)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l7mmvgle65dl92kpqfu9mft7rt